Lexaria and Neutrisci Enter Cannabinoid Joint Venture Kelowna, BC /

Lexaria and Neutrisci Enter Cannabinoid Joint Venture

Kelowna, BC / April 10, 2017 / Lexaria Bioscience Corp

(OTCQB:LXRP) (CSE:LXX) (the Company ) and Neutrisci International Inc

( Neutrisci ) (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed

the previously announced joint venture agreement (the JV ) to produce and

commercialize a line of healthy, sugar-free, edible cannabinoid mouth-melt

products which will utilize Lexaria s patented technology and Neutrisci s

proprietary pterostilbene tablet form factor.

The JV will be named Ambarii Trade Corporation (or similar)

( Ambarii ) and the initial operations will be fully and equally funded by both

Lexaria and Neutrisci. Lexaria and Neutrisci will contribute their respective

technologies to Ambarii by way of license agreement, and share profits derived

from the JV on a 50/50 basis. While there are no immediate plans to do so,

Ambarii will be structured in such a way as to allow for a potential future

spin-off to be created which could provide value to shareholders of both Lexaria

Ambarii intends to secure licensees in California, Colorado and

in Canada to manufacture and sell mouth-melt products containing THC. These

products will combine the benefits of each of Lexaria s and Neutrisci s existing

technologies and ingredient mixes. A licensed California entity is scheduled to

manufacture and test a THC version of the products in June, 2017. In more

developed legal markets such as California and Colorado, cannabis edibles often

comprise 33% - 55% market share of all legal sold cannabis products, making high

quality cannabis edibles vitally important to the marketplace.

Ambarii also intends to develop hemp oil based mouth-melt

products for distribution through networks including Neutrisci s existing

network of retail distributors as well as other methods. Initial test production

runs of the hemp oil variety pterostilbene based products has already achieved

positive human focus group results.

This JV signals a milestone advancement in the cannabis

edibles marketplace with the advent of a novel line of healthy, sugar-free

mouth-melt products, commented Chris Bunka, Lexaria CEO. Lexaria is excited to

have reached this agreement to lever its patented palatability and absorption

enhancing technology for these unique and promising new product offerings.

Glen Rehman, President of NeutriSci stated, We are thrilled to

officially partner with Lexaria. This Agreement represents a giant leap forward

for the development, sale and manufacturing of cannabis edibles. Ambarii will

deliver an edible product that is not only highly effective, but also a healthy

sugar free alternative with the benefits of pterostilbene. The Ambarii product

line will be a world first, and will have high appeal to today s health

conscious medicinal and recreational users.

Lexaria s unique patented

technology allows for more efficient and effective absorption of certain

molecules such as cannabinoids, while simultaneously masking and at times even

eliminating inherent strong flavours and/or odors typical of those molecules.

Lexaria s technology is extremely cost effective to implement and applicable to

a wide spectrum of foods.

Lexaria Bioscience Corp. is a food

biosciences company with a proprietary technology for improved delivery of

bioactive compounds. The Company s lipophilic enhancement technology has been

shown to enhance the bioavailability of orally ingested cannabinoids, while also

masking taste. This technology promotes healthy ingestion methods, lower overall

dosing and higher effectiveness in active molecule delivery. The Company s

technology is patent-protected for cannabidiol (CBD) and all other

non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol

(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs

(NSAIDs), nicotine and other molecules.

NeutriSci specializes in the

innovation, production and formulation of nutraceutical products. Established in

2009, NeutriSci has focused on the development of several breakthrough

nutraceutical products with an initial focus on areas such as heart and

cholesterol health, sleep deprivation therapies, immune defense as well as men's

prostate and sexual health. NeutriSci continues to build strong relationships

and distribution channels for its BluScience and NeuEnergy products with

retailers throughout the United States. NeutriSci is focusing efforts in

strengthening sustainable sales models with Convenience, Chain Drug, and Mass

Market and Supermarket retailers.

FOR FURTHER INFORMATION PLEASE CONTACT:

FORWARD-LOOKING STATEMENTS

This release includes

forward-looking statements. Statements which are not historical facts are

forward-looking statements. The Company makes forward-looking public statements

concerning its expected future financial position, results of operations, cash

flows, financing plans, business strategy, products and services, competitive

positions, growth opportunities, plans and objectives of management for future

operations, including statements that include words such as "anticipate," "if,"

"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"

"will," and other similar expressions are forward-looking statements. Such

forward-looking statements are estimates reflecting the Company's best judgment

based upon current information and involve a number of risks and uncertainties,

and there can be no assurance that other factors will not affect the accuracy of

such forward-looking statements. Factors which could cause actual results to

differ materially from those estimated by the Company include, but are not

limited to, government regulation, managing and maintaining growth, the effect

of adverse publicity, litigation, competition, the patent application and

approval process and other factors which may be identified from time to time in

the Company's public announcements and filings. There is no assurance that the

joint venture with Neutrisci will generate revenue nor provide any other benefit

to Lexaria, or that the Company will experience any growth through participation

in these sectors or as a result of the joint venture. There is no assurance that

existing capital is sufficient for the Company's needs or that it will be able

to raise additional capital. There is no assurance that Lexaria will

successfully complete any other contemplated or existing technology license

agreements, nor that Lexaria s technology will deliver any improvement in taste

or bioavailability with any reliability nor across any product category. There

is no assurance that any planned corporate activity, business venture, or

initiative will be pursued, or if pursued, will be successful. There is no

assurance that any hemp oil or cannabinoid-based product will promote, assist,

or maintain any beneficial human health conditions whatsoever, nor that any

patent application in the USA or any other nation or under any treaty will